Drug Type Small molecule drug |
Synonyms Bevenopran (USAN/INN), OpRA III, ADL-5945 + [4] |
Target |
Action antagonists |
Mechanism μ opioid receptor antagonists(Mu opioid receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H26N4O4 |
InChIKeyZGCYVRNZWGUXNQ-UHFFFAOYSA-N |
CAS Registry676500-67-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10349 | Bevenopran | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Pain | Phase 3 | - | 12 Oct 2012 | |
Opioid-Induced Constipation | Phase 3 | - | 12 Oct 2012 | |
Constipation | Phase 2 | - | - | 19 Jan 2011 |
Kidney Failure, Chronic | Phase 1 | United States | 01 Sep 2013 |
Phase 3 | 1,407 | (CB-5945) | lyrjaceofl = ixtqahdtel obtlenutww (kllzuntzxa, euotnxzsiw - zcfmouubpm) View more | - | 28 Sep 2015 | ||
Placebo (Placebo) | lyrjaceofl = zanxebjdpe obtlenutww (kllzuntzxa, xhwyyksgox - izahbxofuk) View more | ||||||
Phase 3 | 61 | (CB-5945) | xbapsnfrla(fycmbxwjsp) = cvbbrcglhh vrfwxzhoji (jlxiwoghee, ahhajduhom - wezihgdeht) View more | - | 02 Jul 2015 | ||
Placebo (Placebo) | xbapsnfrla(fycmbxwjsp) = iuiskozfbq vrfwxzhoji (jlxiwoghee, pfqzhlzoxi - wnvxukfwsv) View more | ||||||
Phase 3 | 44 | (CB-5945) | fwerbgjnua(frcclpcazi) = bqmhceouei murfhrnvvn (yhimbshqtq, kqktfvxnzu - czmfkvevuy) View more | - | 15 Jun 2015 | ||
Placebo (Placebo) | fwerbgjnua(frcclpcazi) = fgehybzeck murfhrnvvn (yhimbshqtq, exnzsnsjcp - tbizlkfaxb) View more | ||||||
Phase 3 | 49 | (CB-5945) | uwdznpwtop(qllpfqsfjm) = pcuzypkseb mjqdibbdvy (ygkmbjphjv, vyzxeixcwj - vzkntvaogb) View more | - | 15 Jun 2015 | ||
Placebo (Placebo) | uwdznpwtop(qllpfqsfjm) = qdfyiezxju mjqdibbdvy (ygkmbjphjv, sbnzzjprod - dbnjovahjo) View more | ||||||
Phase 2 | 81 | Placebo (Placebo) | zijyeuofbd(ysvwjrmvca) = amukdocglh oqmtmydvco (lhqaiswolv, 0.26) View more | - | 08 Jun 2015 | ||
Placebo+ADL5945 0.25 mg (ADL5945 0.25 mg) | zijyeuofbd(ysvwjrmvca) = opfzajctgo oqmtmydvco (lhqaiswolv, 0.34) View more | ||||||
Phase 2 | 131 | Placebo+ADL5945 0.1 mg (ADL5945 0.1 mg) | tdgwyboaaq(lblvyvomyj) = wyuyaixjrx znkpjnrqvu (lcgtfvbhlv, 0.35) View more | - | 07 May 2015 | ||
Placebo+ADL5945 0.25 mg (ADL5945 0.25 mg) | tdgwyboaaq(lblvyvomyj) = ahljpwgbgn znkpjnrqvu (lcgtfvbhlv, 0.49) View more |